<p>LINC00518 Interference Inhibits Non–Small Cell Lung Cancer by Upregulating miR216b-5p Expression</p>

Abstract

Introduction Non–small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases, and effective treatment for this disease is still lacking. This study aimed to explore the potential role of LINC00518 and miR216b-5p on cell proliferation and tumor growth in NSCLC. Methods The expression of LINC00518, miR216b-5p, MMP7, and MMP9 in NSCLC cell lines was determined by RT-qPCR analysis, which was also used to confirm the transfection effects. After transfection, proliferation, clone-formation ability, migration, and invasion of NSCLC cells were detected by CCK8, clone-formation, wound-healing, and transwell assays, respectively. Western blot analysis was used to detect the expression of MMP7, MMP9, Ki67, and PCNA. A xenograft model was constructed by subcutaneous injection of transfected NSCLC cells into nude mice. Results The results indicated that LINC00518 expression was increased and miR216b-5p expression decreased in NSCLC cell lines, and A549 cells were chosen for the next experiments. LINC00518 interference inhibited proliferation, invasion, and migration of A549 cells, together with the progression of NSCLC in vivo. In addition, LINC00518 directly targeted miR216b-5p. Downregulation of miR216b-5p weakened the inhibitory effect of LINC00518 interference on proliferation, invasion, and migration of A549 cells, as well as progression of NSCLC in vivo. Discussion In conclusion, LINC00518 interference inhibits NSCLC, which is partially reversed by downregulation of miR216b-5p expression.

Development and validation of a ferroptosis-related lncRNAs signature to predict prognosis and microenvironment for melanoma

“…The SKCM predictive signature was successfully constructed with 19 FRLs, including 13 protective factors (CCR5AS, EBLN3P, HLA-DQB1-AS1, LINC00861, LINC01094, SPRY4-AS1, USP30-AS1, TRBV11-2, and WAC-AS1) and six risk factors (LINC00518 and LURAP1L-AS1). For example, LINC00518 is a tumor-promoting factor in multiple tumors, including lung adenocarcinoma [ 47 ], cervical [ 48 ], breast [ 49 ], and non-small cell lung cancer [ 50 ]. Similarly, it was found that LINC00518 promoted the migration, invasion, and metastasis of melanoma through the miR-204-5p/AP1S2 [ 51 ] and miR-33a-3p/HIF-1α [ 52 ] axes, which is consistent with our finding that LINC00518 serves as a risk factor for SKCM.…”

The Hypoxia–Long Noncoding RNA Interaction in Solid Cancers

“…LINC00518 is potentially involved in cancer-related processes, such as cell viability, migration, invasion, and metastasis [ 197 , 198 , 199 , 200 ]. Furthermore, LINC00518 can promote therapeutic resistance to various agents, including paclitaxel, vincristine, and adriamycin [ 201 , 202 ].…”